Indication

Acute Phase

1 clinical trial

1 product

Clinical trial

Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study

Status: Recruiting, Estimated PCD: 2024-03-20

Product